Dailypharm Live Search Close

[Reporter’s View] Next year wishes for the industry

By An, Kyung-Jin | translator Byun Kyung A

19.12.30 06:12:47

가나다라 0



“Last year, not one of Korean-made new drug was approved by the U.S. Food and Drug Administration (FDA). Ever since hemophilia treatment Aftyla was passed in 2016, Korean drugs have not been able to get a green light from the U.S. health regulator for two consecutive years. However, the industry is expected to bring a series of good news this year about Korean drugs entering the U.S. market.”

In the beginning for the year, Daily Pharm had opened an article with the lead. And as predicted, Korean pharmaceutical and bio companies had a year filled with good news.

Starting from Yuhan closing a license-out deal with Gilead Sciences on candidate medicine for non-alcoholic steatohepatitis

An, Kyung-Jin(kjan@dailypharm.com)
If you want to see the full article, please JOIN US (click)